Open Access
Oncotarget, volume 8, issue 43, pages 75038-75049
Immethridine, histamine H3-receptor (H3R) agonist, alleviated experimental autoimmune encephalomyelitis via inhibiting the function of dendritic cells
Publication type: Journal Article
Publication date: 2017-08-24
Oncology
Abstract
Multiple sclerosis (MS) is an inflammatory disease that is characterized by immune-mediated demyelination and degeneration of the central nervous system (CNS). Experimental autoimmune encephalomyelitis (EAE) is the preferential experimental rodent model for MS. Previous study demonstrated histamine H3 receptor (H3R) was an important factor in pathophysiology of EAE and immethridine was the most selective agonist of H3R. However, whether immethridine has therapeutic effect on EAE and its mechanism remained to be defined. Here we constructed EAE mouse model by immunization of MOG35-55 peptides with complete Freund's adjuvant, immethridine was used to treat EAE and its therapeutic effect was evaluated. The results showed that the treatment of immethridine could alleviate EAE. The percentage of Th1 and Th17 in the spleen from the treated EAE mice decreased and the surface molecules such as CD40, CD86 or MHCII on dendritic cells (DCs) were also down-regulated. To understand the effect of immethridine on DCs, bone marrow-derived DCs were prepared and the immunological functions were analyzed. The data demonstrated that immethridine could change the expression profiles of cytokines in DCs and inhibit the expression of the co-stimulatory molecules such as CD40 and CD86. Furthermore, immethridine also inhibited the antigen-presenting function of DCs and T cell differentiation induced by DCs. Signaling pathway analysis demonstrated that the phosphorylation of NF-κB p65 but not ERK1/2 in DCs was inhibited after the treatment of immethridine. These data strongly suggested that immethridine could inhibit the function of DCs and indicated the therapeutic potential on EAE.
Citations by journals
|
1
|
|
|
ACS Chemical Neuroscience
1 publication, 9.09%
|
|
|
Pharmaceutics
1 publication, 9.09%
|
|
|
Frontiers in Immunology
1 publication, 9.09%
|
|
|
Drugs
1 publication, 9.09%
|
|
|
Naunyn-Schmiedeberg's Archives of Pharmacology
1 publication, 9.09%
|
|
|
Pharmacology Biochemistry and Behavior
1 publication, 9.09%
|
|
|
Journal of Drug Delivery Science and Technology
1 publication, 9.09%
|
|
|
CNS Neuroscience and Therapeutics
1 publication, 9.09%
|
|
|
Current Topics in Behavioral Neurosciences
1 publication, 9.09%
|
|
|
Frontiers in Cell and Developmental Biology
1 publication, 9.09%
|
|
|
Progress in Brain Research
1 publication, 9.09%
|
|
|
1
|
Citations by publishers
|
1
2
3
|
|
|
Springer Nature
3 publications, 27.27%
|
|
|
Elsevier
3 publications, 27.27%
|
|
|
Frontiers Media S.A.
2 publications, 18.18%
|
|
|
American Chemical Society (ACS)
1 publication, 9.09%
|
|
|
Multidisciplinary Digital Publishing Institute (MDPI)
1 publication, 9.09%
|
|
|
Wiley
1 publication, 9.09%
|
|
|
1
2
3
|
- We do not take into account publications that without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.
{"yearsCitations":{"type":"bar","data":{"show":true,"labels":[2018,2019,2020,2021,2022,2023],"ids":[0,0,0,0,0,0],"codes":[0,0,0,0,0,0],"imageUrls":["","","","","",""],"datasets":[{"label":"Citations number","data":[1,3,0,3,2,2],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":["9.09","27.27",0,"27.27","18.18","18.18"],"barThickness":null}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"journals":{"type":"bar","data":{"show":true,"labels":["ACS Chemical Neuroscience","Pharmaceutics","Frontiers in Immunology","Drugs","Naunyn-Schmiedeberg's Archives of Pharmacology","Pharmacology Biochemistry and Behavior","Journal of Drug Delivery Science and Technology","CNS Neuroscience and Therapeutics","Current Topics in Behavioral Neurosciences","Frontiers in Cell and Developmental Biology","Progress in Brain Research"],"ids":[5507,4502,1699,413,5278,4681,17907,21557,18467,12128,12159],"codes":[0,0,0,0,0,0,0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/iLiQsFqFaSEx6chlGQ5fbAwF6VYU3WWa08hkss0g_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp"],"datasets":[{"label":"","data":[1,1,1,1,1,1,1,1,1,1,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[9.09,9.09,9.09,9.09,9.09,9.09,9.09,9.09,9.09,9.09,9.09],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Journals","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"publishers":{"type":"bar","data":{"show":true,"labels":["Springer Nature","Elsevier","Frontiers Media S.A.","American Chemical Society (ACS)","Multidisciplinary Digital Publishing Institute (MDPI)","Wiley"],"ids":[8,17,208,40,202,11],"codes":[0,0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/iLiQsFqFaSEx6chlGQ5fbAwF6VYU3WWa08hkss0g_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp"],"datasets":[{"label":"","data":[3,3,2,1,1,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[27.27,27.27,18.18,9.09,9.09,9.09],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Publishers","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}}}
Metrics
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Shi Y. et al. Immethridine, histamine H3-receptor (H3R) agonist, alleviated experimental autoimmune encephalomyelitis via inhibiting the function of dendritic cells // Oncotarget. 2017. Vol. 8. No. 43. pp. 75038-75049.
GOST all authors (up to 50)
Copy
Shi Y., Li Z., Chen R., Zhang J., HU X., He C., Su Q., Ma H., Ren H., Qian M., Cui S., Jiang W. Immethridine, histamine H3-receptor (H3R) agonist, alleviated experimental autoimmune encephalomyelitis via inhibiting the function of dendritic cells // Oncotarget. 2017. Vol. 8. No. 43. pp. 75038-75049.
Cite this
RIS
Copy
TY - JOUR
DO - 10.18632/oncotarget.20500
UR - https://doi.org/10.18632/oncotarget.20500
TI - Immethridine, histamine H3-receptor (H3R) agonist, alleviated experimental autoimmune encephalomyelitis via inhibiting the function of dendritic cells
T2 - Oncotarget
AU - Shi, Yaru
AU - Li, Zhenlong
AU - Chen, Ran
AU - Zhang, Jiang
AU - HU, XUEFEI
AU - He, Cong
AU - Su, Qiong
AU - Ma, Hongdou
AU - Ren, Hua
AU - Qian, Min
AU - Cui, Shufang
AU - Jiang, Wenzheng
PY - 2017
DA - 2017/08/24 00:00:00
PB - Impact Journals
SP - 75038-75049
IS - 43
VL - 8
SN - 1949-2553
SN - 1949-2553
ER -
Cite this
BibTex
Copy
@article{2017_Shi,
author = {Yaru Shi and Zhenlong Li and Ran Chen and Jiang Zhang and XUEFEI HU and Cong He and Qiong Su and Hongdou Ma and Hua Ren and Min Qian and Shufang Cui and Wenzheng Jiang},
title = {Immethridine, histamine H3-receptor (H3R) agonist, alleviated experimental autoimmune encephalomyelitis via inhibiting the function of dendritic cells},
journal = {Oncotarget},
year = {2017},
volume = {8},
publisher = {Impact Journals},
month = {aug},
url = {https://doi.org/10.18632/oncotarget.20500},
number = {43},
pages = {75038--75049},
doi = {10.18632/oncotarget.20500}
}
Cite this
MLA
Copy
Shi, Yaru, et al. “Immethridine, histamine H3-receptor (H3R) agonist, alleviated experimental autoimmune encephalomyelitis via inhibiting the function of dendritic cells.” Oncotarget, vol. 8, no. 43, Aug. 2017, pp. 75038-75049. https://doi.org/10.18632/oncotarget.20500.